Prospective study of predictor for efficiency of treatment with Nintedanib for idiopathic pulmonary fibrosis

Trial Profile

Prospective study of predictor for efficiency of treatment with Nintedanib for idiopathic pulmonary fibrosis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 08 Oct 2017 Planned End Date changed from 30 Sep 2018 to 31 Mar 2019.
    • 27 Sep 2016 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
    • 18 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top